TVTX vs VERA
TVTX: A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need. VERA: Vera Therapeutics is a commercial-stage biotech pioneer targeting B-cell-driven autoimmune diseases, currently focused on its lead BAFF/APRIL inhibitor for IgA nephropathy.
Side-by-side fundamentals
| Metric | TVTX | VERA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $52.04 | $29.73 | |
| Market cap | $4.9B | $2.1B | |
| Net margin FY2025, SEC XBRL | -5.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -12.8% | n/a | |
| ROE FY2025, SEC XBRL | -22.2% | -49.6% | TVTX higher |
| ROA FY2025, SEC XBRL | -4.2% | -40.8% | TVTX higher |
| Debt / equity as of 2026-09-02 | 24.58 | 0.15 | VERA lower |
| Revenue growth (YoY) as of 2026-09-02 | +77.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +64.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.22 | 1.13 | |
| 1-year return as of 2026-10-08 close | +98.6% | -2.5% | TVTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.